SWINE REPRODUCTIVE AND RESPIRATORY SYNDROME VACCINE MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST

  2024-11-27 |   Pages: 200+ |   Report ID: MD-R-2024-11-27-162738 |   Pharmaceuticals and Healthcare

Historical data: 2018 - 2023

Forecast period: 2024 - 2031

Quantitative units: Revenue in USD million and CAGR from 2024 to 2031

Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Swine Reproductive and Respiratory Syndrome Vaccine Market

Image

1.1 SCOPE OF THE REPORT

1.2 MARKET SEGMENT ANALYSIS

1.3 REGULATORY SCENARIO BY REGION/COUNTRY

1.4 MARKET INVESTMENT SCENARIO STRATEGIC

1.5 MARKET ANALYSIS BY TYPE (USD MILLION)

1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)

2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS

  2.1.1 MARKET DRIVER ANALYSIS

  2.1.2 MARKET RESTRAINT ANALYSIS

  2.1.3 MARKET OPPORTUNITY

  2.1.4 MARKET CHALLENGES

3.1 INDUSTRY TRENDS

  3.1.1 SWOT ANALYSIS

  3.1.2 PESTEL ANALYSIS

  3.1.3 PORTER’S FIVE FORCES ANALYSIS

3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS

4.1 COVID-19 ANALYSIS

5.1 GLOBAL SWINE REPRODUCTIVE AND RESPIRATORY SYNDROME VACCINE MARKET, SALES AREA, TYPE

5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL SWINE REPRODUCTIVE AND RESPIRATORY SYNDROME VACCINE MARKET

7.1 GLOBAL SWINE REPRODUCTIVE AND RESPIRATORY SYNDROME VACCINE MARKET SIZE AND SHARE (2018-2031) (USD MILLION)

8.1 GLOBAL SWINE REPRODUCTIVE AND RESPIRATORY SYNDROME VACCINE MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

8.2 GLOBAL SWINE REPRODUCTIVE AND RESPIRATORY SYNDROME VACCINE MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

9.1 GLOBAL SWINE REPRODUCTIVE AND RESPIRATORY SYNDROME VACCINE MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

9.2 GLOBAL SWINE REPRODUCTIVE AND RESPIRATORY SYNDROME VACCINE MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

10.1 GLOBAL SWINE REPRODUCTIVE AND RESPIRATORY SYNDROME VACCINE MARKET SIZE AND SHARE BY REGION (2018-2023) (USD MILLION)

10.2 GLOBAL SWINE REPRODUCTIVE AND RESPIRATORY SYNDROME VACCINE MARKET SIZE AND SHARE BY REGION (2024-2031) (USD MILLION)

11.1 NORTH AMERICA SWINE REPRODUCTIVE AND RESPIRATORY SYNDROME VACCINE MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

11.2 NORTH AMERICA SWINE REPRODUCTIVE AND RESPIRATORY SYNDROME VACCINE MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

11.3 NORTH AMERICA SWINE REPRODUCTIVE AND RESPIRATORY SYNDROME VACCINE MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

11.4 NORTH AMERICA SWINE REPRODUCTIVE AND RESPIRATORY SYNDROME VACCINE MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

11.5 NORTH AMERICA SWINE REPRODUCTIVE AND RESPIRATORY SYNDROME VACCINE MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

11.6 NORTH AMERICA SWINE REPRODUCTIVE AND RESPIRATORY SYNDROME VACCINE MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

12.1 EUROPE SWINE REPRODUCTIVE AND RESPIRATORY SYNDROME VACCINE MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

12.2 EUROPE SWINE REPRODUCTIVE AND RESPIRATORY SYNDROME VACCINE MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

12.3 EUROPE SWINE REPRODUCTIVE AND RESPIRATORY SYNDROME VACCINE MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

12.4 EUROPE SWINE REPRODUCTIVE AND RESPIRATORY SYNDROME VACCINE MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

12.5 EUROPE SWINE REPRODUCTIVE AND RESPIRATORY SYNDROME VACCINE MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

12.6 EUROPE SWINE REPRODUCTIVE AND RESPIRATORY SYNDROME VACCINE MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

13.1 ASIA PACIFIC SWINE REPRODUCTIVE AND RESPIRATORY SYNDROME VACCINE MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

13.2 ASIA PACIFIC SWINE REPRODUCTIVE AND RESPIRATORY SYNDROME VACCINE MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

13.3 ASIA PACIFIC SWINE REPRODUCTIVE AND RESPIRATORY SYNDROME VACCINE MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

13.4 ASIA PACIFIC SWINE REPRODUCTIVE AND RESPIRATORY SYNDROME VACCINE MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

13.5 ASIA PACIFIC SWINE REPRODUCTIVE AND RESPIRATORY SYNDROME VACCINE MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

13.6 ASIA PACIFIC SWINE REPRODUCTIVE AND RESPIRATORY SYNDROME VACCINE MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

14.1 LATIN AMERICA SWINE REPRODUCTIVE AND RESPIRATORY SYNDROME VACCINE MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)/p>

14.2 LATIN AMERICA SWINE REPRODUCTIVE AND RESPIRATORY SYNDROME VACCINE MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

14.3 LATIN AMERICA SWINE REPRODUCTIVE AND RESPIRATORY SYNDROME VACCINE MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

14.4 LATIN AMERICA SWINE REPRODUCTIVE AND RESPIRATORY SYNDROME VACCINE MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

14.5 LATIN AMERICA SWINE REPRODUCTIVE AND RESPIRATORY SYNDROME VACCINE MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

14.6 LATIN AMERICA SWINE REPRODUCTIVE AND RESPIRATORY SYNDROME VACCINE MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

15.1 MIDDLE EAST & AFRICA SWINE REPRODUCTIVE AND RESPIRATORY SYNDROME VACCINE MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

15.2 MIDDLE EAST & AFRICA SWINE REPRODUCTIVE AND RESPIRATORY SYNDROME VACCINE MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

15.3 MIDDLE EAST & AFRICA SWINE REPRODUCTIVE AND RESPIRATORY SYNDROME VACCINE MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

15.4 MIDDLE EAST & AFRICA SWINE REPRODUCTIVE AND RESPIRATORY SYNDROME VACCINE MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

15.5 MIDDLE EAST & AFRICA SWINE REPRODUCTIVE AND RESPIRATORY SYNDROME VACCINE MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

15.6 MIDDLE EAST & AFRICA SWINE REPRODUCTIVE AND RESPIRATORY SYNDROME VACCINE MARKET SIZE AND SHARE BY APPLICATION (2024-2031)< (USD MILLION)/p>

16.1 ASCENT CORPORATION

  16.1.1 COMPANY DETAILS

  16.1.2 FINANCIALS (USD MILLION)

  16.1.3 PRODUCT SUMMARY

  16.1.4 RECENT DEVELOPMENTS

16.2 Boehringer-Ingelheim

16.3 MSD Animal Health

16.4 SPAH

16.5 Ceva

16.6 Chengdu TECH-BANK Biological Products Co .Ltd

16.7 ringpu

16.8 QILU ANIMAL HEALTH PRODUCTS CO. LTD

16.9 DAHUANONG

16.10 CAVAC

16.11 Komipharm

16.12 Agrovet

16.13 Bioveta

16.14 JINYU BIO-TECNOLOGY CO. LTD

16.15 Phibro Animal Health

16.16 ANHUI TIANKANG(GROUP)SHRES O. LTD

16.17 Zoetis

16.18 WINSUN BIO

16.19 PULIKE BIOLOGICAL ENGINERING INC.

18.1 METHODOLOGY

18.2 RESEARCH DATA SOURCE

  18.2.1 SECONDARY DATA

  18.2.2 KEY DATA FROM SECONDARY

  18.2.3 PRIMARY DATA

  18.2.4 KEY DATA FROM PRIMARY

  18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS

  18.2.6 MARKET ESTIMATION

  18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH

  18.2.8 LEGAL DISCLAIMER

Market Segments

By Type

Active Vaccine
Inactivated Vaccines

By Application

Government Tender
Market Sales

Companies

ASCENT CORPORATION
Boehringer-Ingelheim
MSD Animal Health
SPAH
Ceva
Chengdu TECH-BANK Biological Products Co .Ltd
ringpu
QILU ANIMAL HEALTH PRODUCTS CO. LTD
DAHUANONG
CAVAC
Komipharm
Agrovet
Bioveta
JINYU BIO-TECNOLOGY CO. LTD
Phibro Animal Health
ANHUI TIANKANG(GROUP)SHRES O. LTD
Zoetis
WINSUN BIO
PULIKE BIOLOGICAL ENGINERING INC.

BROWSE INDUSTRY

  1. Consumer Goods
  2. Healthcare
  3. Food & Beverage
  4. Heavy Industry
  5. Service Industries
  6. FMCG
  7. Life Sciences
  8. Technology & Media
  9. Machinery & Equipment

    WHY CHOOSE US

  •   PROACTIVE
  • We manage our resources 24/7 to identify issues and address them before they become problems.

  •   QUALITY & RELIABILITY
  • We are committed to providing reliable and highly accurate data with an excellent quality control system.

  •   GLOBAL OUTREACH
  • 6 Major regions and 40+ countries level analysis accomplished.

  •   COMPETITIVE PRICING
  • Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.